Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
SAN RAMON, Calif., Oct. 31, 2016 -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that the Company will present at the Credit Suisse Healthcare Conference in Scottsdale, AZ. During the presentation, Mr. Jonathan Rigby, President & CEO, will provide an overview and update on the Company's business.
Date: Monday, November 7, 2016
Time: 2:00 pm MT
Location: The Phoenician – Scottsdale, AZ
An audio webcast of the Company’s presentation will be available online at SteadyMed’s website www.steadymed.com. A replay of the presentation will be available for 90 days.
About SteadyMed
SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent®, a development stage drug product that combines SteadyMed's PatchPump® technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). SteadyMed intends to commercialize Trevyent in the U.S. and has signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit www.steadymed.com.
Contacts: Marylyn Rigby Senior Director, Investor Relations and Marketing 925-272-4999 [email protected] The Ruth Group David Burke (646) 536-7009 [email protected]
